IGF1 and hepatocellular carcinoma: Furthermore, experimental studies have shown that IGF and FGF signaling are partly responsible for acquired resistance to sorafenib treatment in patients with HCC, and restraining the activation of these pathways will benefit some patients who progress after treatment with sorafenib.77